Leadership Team – New Life Biologics
Simon Egan
President, New Life Biologics
As President of New Life Biologics, Simon plays a pivotal role in shaping the company’s overall strategy, direction, and investor and supply strategies. With a rich background in the animal byproduct supply industry, Simon is a major shareholder, director, and former CEO of Greenlea Meats, a prominent New Zealand beef processor and exporter. He previously co-founded BioArra, a US-based manufacturer specializing in high-value serum products for the scientific and pharmaceutical markets, which was acquired by VWR in 2016.
In addition, Simon is a shareholder in Advanced Life Bio, a US-based serum manufacturer, and a founding shareholder in Astrea Farinhas E Oleos S/A, a poultry by-products processor based in Brazil. His extensive experience and commitment to the biologics industry are crucial to his leadership role at New Life Biologics.
Randal Fitzgerald
CEO, New Life Biologics
The CEO of New Life Biologics, Randal Fitzgerald, is responsible for strategy and the management of day-to-day operations, including quality control, regulatory initiatives, and technical sales. With over 30 years of experience in developing animal by-product based technologies for various industries, including diagnostics, medical devices, pharmaceuticals, biopharmaceuticals, and agriculture, his track record speaks for itself. He previously served as the COO of Proliant Biologicals and has led product development for Fortune 500 companies.
Randal’s expertise extends to building international facilities, negotiating with authorities, and managing operations. He has also contributed to industry associations, serving as Vice Chair and board member of the International Serum Industry Association, and being a member of the International Society of Pharmaceutical Engineers for 25 years.
Rosemary Versteegen, PhD
Technical Advisor, New Life Biologics
Dr Versteegen received her B.Sc. and Ph.D. degrees in Biochemistry from Glasgow University, Scotland. She held Postdoctoral scholarships at Cambridge University, England and the National Institutes of Health working in areas of disease research. Following several years in NIH sponsored cancer research programs, she joined Life Technologies and held various key roles, both technical and business oriented, including Vice President of the GIBCO Manufacturing Facility, Vice President of Regulatory Affairs, Vice President of New Business Development, and Vice President of Strategic Planning.
In 2000, Dr Versteegen became a founding partner of the Lifia Group, a consulting organization focused on helping life science and biotechnology companies grow through clearly enunciated, actionable strategic plans From its inception in 2006 through 2023, Dr Versteegen was the CEO of the International Serum Industry Association, a global life science not-for-profit association. Since retiring from that position Rosie has been the Technical Advisor to New life Biologics, responsible for technical and marketing activities.
